Skip to main content
. 2022 Feb;33(2):401–419. doi: 10.1681/ASN.2021050643

Table 7a.

Time to steroid dependence: Throughout the treatment period and follow-up period

Group No. of Patients No. of Patients with Frequent Relapses No. of Patients with Steroid Resistance as Competing Event No. of Patients Censored Median (95% CI) (days) Hazard Ratio (95% CI) Gray Test
MMF 39 22 1 16 853.0 (593.0 to 1299.0) 0.602 (0.34 to 1.08) P=0.08
Placebo 39 24 0 15 452.0 (360.0 to not reached)